OKYO Pharma Ltd

OKYO chart

OKYO Pharma Ltd news

• OKYO Pharma Limited Estimates – NASDAQ:OKYO

  TradingView · Oct 25, 1:24 PM EDT

• Analysts Are Bullish on Top Healthcare Stocks: Ocular Therapeutix (OCUL), Palvella Therapeutics (PVLA)

  The Globe and Mail · Oct 21, 6:36 AM EDT

• OKYO Pharma Begins Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal Pain

  Yahoo Finance · Oct 6, 10:09 AM EDT

• OKYO Pharma enrolls first patients in Phase 3 trial of neuropathic corneal pain drug

  proactiveinvestors.com · Oct 6, 8:30 AM EDT

• OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain

  Yahoo Finance · Oct 6, 7:00 AM EDT

• OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences

  Yahoo Finance · Sep 29, 7:00 AM EDT

• OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026

  Yahoo Finance · Sep 9, 7:00 AM EDT

• OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference

  Yahoo Finance · Sep 8, 7:00 AM EDT

• OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

  Yahoo Finance · Jul 28, 7:00 AM EDT

• OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026

  Yahoo Finance · Jul 27, 7:00 AM EDT

• OKYO Pharma Announces Purchase of Shares by Director

  Yahoo Finance · Jul 23, 12:00 PM EDT

• OKYO Pharma Announces Purchase of Shares by Chairman

  Yahoo Finance · Jul 22, 12:00 PM EDT

OKYO Pharma Ltd key financials

No XBRL financial data is available for this company yet.

Calendar-year figures as reported to the SEC in XBRL filings.

Recent SEC filings

• 6-K6-K2026-10-06
• 6-K6-K2026-09-29
• 6-K6-K2026-09-09
• 6-K6-K2026-09-08
• 6-K6-K2026-07-28
• 6-K6-K2026-07-27
• 6-K6-K2026-07-23
• 6-K6-K2026-07-23
• 6-K6-K2026-07-22
• 6-K6-K2026-07-22
• 6-K6-K2026-07-22
• 6-K6-K2026-07-21

About OKYO Pharma Ltd

Ticker

OKYO (Nasdaq)

Industry

Biological Products, (No Diagnostic Substances)

Headquarters

London, United Kingdom

SEC CIK

1849296

Frequently asked questions